Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus

This study investigated whether rosiglitazone may affect breast cancer risk in female patients with type 2 diabetes mellitus in Taiwan. The reimbursement database of all female patients with type 2 diabetes mellitus under oral antidiabetic agents or insulin from 1996 to 2009 was retrieved from the N...

Descripción completa

Detalles Bibliográficos
Autor principal: Tseng, Chin-Hsiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356862/
https://www.ncbi.nlm.nih.gov/pubmed/27936468
http://dx.doi.org/10.18632/oncotarget.13824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356862/
https://www.ncbi.nlm.nih.gov/pubmed/27936468
http://dx.doi.org/10.18632/oncotarget.13824

Ejemplares similares